3//SEC Filing
SVLSF V, LLC 3
Accession 0001104659-19-031226
CIK 0001761612other
Filed
May 21, 8:00 PM ET
Accepted
May 22, 9:37 PM ET
Size
16.2 KB
Accession
0001104659-19-031226
Insider Transaction Report
Form 3
SV Life Sciences Fund V (GP), LP
10% Owner
Holdings
- (indirect: By SV Life Sciences Fund V, L.P.)
Series A Preferred Shares
→ Ordinary Shares (874,709 underlying) - (indirect: By SV Life Sciences Fund V, L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (623,196 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (13,169 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series A Preferred Shares
→ Ordinary Shares (18,485 underlying)
SVLSF V, LLC
10% Owner
Holdings
- (indirect: By SV Life Sciences Fund V, L.P.)
Series A Preferred Shares
→ Ordinary Shares (874,709 underlying) - (indirect: By SV Life Sciences Fund V, L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (623,196 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series A Preferred Shares
→ Ordinary Shares (18,485 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (13,169 underlying)
SV LIFE SCIENCES FUND V LP
10% Owner
Holdings
- (indirect: By SV Life Sciences Fund V, L.P.)
Series A Preferred Shares
→ Ordinary Shares (874,709 underlying) - (indirect: By SV Life Sciences Fund V, L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (623,196 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series A Preferred Shares
→ Ordinary Shares (18,485 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (13,169 underlying)
Holdings
- (indirect: By SV Life Sciences Fund V, L.P.)
Series A Preferred Shares
→ Ordinary Shares (874,709 underlying) - (indirect: By SV Life Sciences Fund V, L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (623,196 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series A Preferred Shares
→ Ordinary Shares (18,485 underlying) - (indirect: By SV Life Sciences Fund V Strategic Partners L.P.)
Series B1 Preferred Shares
→ Ordinary Shares (13,169 underlying)
Footnotes (4)
- [F1]Each share of Series A Preferred and Series B1 Preferred shall automatically convert into Ordinary shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering of Ordinary Shares and have no expiration date.
- [F2]Share numbers give effect to the bonus shares issued to each holder of ordinary shares on the basis of 1.429 bonus shares for each ordinary share in issue, effective on May 13, 2019, which will be effective for the ordinary shares upon their conversion to ordinary shares upon the closing of the Issuer's initial public offering. The number of shares reflects the conversion of the Series A Preferred Shares and Series B1 Preferred Shares to Ordinary Shares set out in footnote (1) above.
- [F3]These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- [F4]These shares are owned directly by SV Life Sciences Fund V Strategic Partners L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein
Documents
Issuer
BICYCLE THERAPEUTICS Ltd
CIK 0001761612
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001644160
Filing Metadata
- Form type
- 3
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 9:37 PM ET
- Size
- 16.2 KB